摘要
目的探讨丙酮酸激酶剪接体M1型(PKM1)和M2型(PKM2)在不同慢性粒细胞白血病(chronic myeloid leukemia,CML)细胞中的表达情况及意义。方法收集南昌大学第二附属医院确诊的伊马替尼(Imatinib,IM)敏感(n=23)和IM耐药(n=7)CML患者外周血或骨髓,采用逆转录-聚合酶链反应(reverse transcription-polymerase chain reaction,RT-PCR)的方法检测IM敏感CML细胞系K562、IM耐药CML细胞系K562/G01及30例临床样本中PKM1和PKM2表达水平。结果与K562细胞相比,K562/G01细胞中PKM2/PKM1的比值明显升高;IM耐药CML患者PKM2/PKM1的比值较IM敏感者显著上调。结论 PKM发生异常剪接可能与CML细胞IM耐药相关。
Objective To explore the expression levels and effects of the pymvate kinase spliccesome PKMI and PKM2 in different chronic myeloid leukemia （CML） cells. Methods CML patients diagnosed as imatinib （IM） sensitive （n=23） and IM resis- tant （n=7） were enrolled from the second affiliated hospital of Nanchang university,respectively. PKM1 and PKM2 mRNA levels were detected by reverse transcription-polymerase chain reaction （RT-PCR） in IM sensitive cell line （K562）,IM resistant cell line （K562/G01） and 30 clinical samples. Results PKM2/PKM1 ratio was significantly higher in K562/G01 compared with that in k562;the PKM2/PKM1 ratio in IM resistant patient was also obviously higher than that in IM sensitive patient. Conclusion Aber- rant splicing of PKM is probably related to Imatinib resistance in CML cells.
出处
《实验与检验医学》
CAS
2017年第2期140-142,共3页
Experimental and Laboratory Medicine
基金
国家自然科学基金项目(编号81271912)
